AMANDA DOZIER: Open Payments
NPI 1548644099 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$200 in 12 payments from 10 companies in 2025. Trend: 2023 $375 · 2024 $289 · 2025 $200
Food & beverage: $200
| Company | Payments | Amount |
|---|---|---|
| Viatris Specialty LLC | 3 | $47 |
| Exeltis, USA Inc. | 1 | $22 |
| Novo Nordisk Inc | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Amgen Inc. | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
| SANOFI PASTEUR INC. | 1 | $15 |
| PFIZER INC. | 1 | $14 |
| Corium, LLC | 1 | $12 |
Products named: YUPELRI, SLYND, Ozempic, REXULTI, RECORLEV, EVENITY, FARXIGA, BEYFORTUS.
Industry payments across ID — which companies pay providers there.
